

Caroline Pabst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2258609/publications.pdf>

Version: 2024-02-01

26
papers

1,522
citations

566801

15
h-index

642321

23
g-index

29
all docs

29
docs citations

29
times ranked

3138
citing authors

#	ARTICLE	IF	CITATIONS
1	Vesicular trafficking is a key determinant of the statin response in acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 509-514.	2.5	4
2	Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation. <i>Vaccines</i> , 2022, 10, 330.	2.1	9
3	CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia. <i>EMBO Molecular Medicine</i> , 2022, 14, e14990.	3.3	14
4	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranilcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. <i>Leukemia</i> , 2021, 35, 701-711.	3.3	56
5	Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. <i>Nature Communications</i> , 2021, 12, 1366.	5.8	69
6	Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. <i>Nature Cancer</i> , 2021, 2, 527-544.	5.7	37
7	RSPO2 inhibits BMP signaling to promote self-renewal in acute myeloid leukemia. <i>Cell Reports</i> , 2021, 36, 109559.	2.9	10
8	Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study. <i>Blood</i> , 2021, 138, 4418-4418.	0.6	3
9	Cooperating mutations: joint forces, novel vulnerabilities. <i>Blood</i> , 2020, 135, 785-787.	0.6	2
10	Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation. <i>Blood</i> , 2020, 135, 2059-2070.	0.6	52
11	The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2830-2841.	3.3	30
12	Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. <i>Blood</i> , 2019, 134, 263-276.	0.6	41
13	Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. <i>Leukemia</i> , 2018, 32, 1349-1357.	3.3	31
14	MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2627-2627.	0.6	3
15	Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. <i>Nature Medicine</i> , 2017, 23, 69-78.	15.2	192
16	AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. <i>Nature Cell Biology</i> , 2017, 19, 844-855.	4.6	132
17	RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. <i>Nature Communications</i> , 2017, 8, 2126.	5.8	91
18	Adhesion GPCRs in Regulating Immune Responses and Inflammation. <i>Advances in Immunology</i> , 2017, 136, 163-201.	1.1	59

#	ARTICLE	IF	CITATIONS
19	GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. Blood, 2016, 127, 2018-2027.	0.6	148
20	Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors. Blood, 2016, 127, 3054-3061.	0.6	70
21	Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell, 2015, 27, 658-670.	7.7	341
22	Transcriptome Analysis Reveals That G Protein-Coupled Receptors Are Potential Diagnostic Markers or Therapeutic Targets in Acute Myeloid Leukemia. Blood, 2015, 126, 3855-3855.	0.6	2
23	The Novel Leukemia Stem Cell Marker GPR56 Discriminates Leukemic Subclones with Divergent Stem Cell Properties in Human Acute Myeloid Leukemia. Blood, 2015, 126, 1859-1859.	0.6	0
24	Identification of small molecules that support human leukemia stem cell activity ex vivo. Nature Methods, 2014, 11, 436-442.	9.0	115
25	Novel Targeting Strategies for Leukemia-Initiating Cells in Myeloid Neoplasms. Blood, 2013, 122, SCI-27-SCI-27.	0.6	0
26	A High-Throughput Screen to Identify Compounds Preserving Primary Human AML Stem Cells Ex-Vivo,. Blood, 2011, 118, 3587-3587.	0.6	0